RENAU.UNSP.ARD 1/5 EO-20 (56S0) - Total Liabilities
Based on the latest financial reports, RENAU.UNSP.ARD 1/5 EO-20 (56S0) has total liabilities worth €3.86 Billion EUR (≈ $4.51 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore RENAU.UNSP.ARD 1/5 EO-20 cash flow conversion to assess how effectively this company generates cash.
RENAU.UNSP.ARD 1/5 EO-20 - Total Liabilities Trend (2022–2025)
This chart illustrates how RENAU.UNSP.ARD 1/5 EO-20's total liabilities have evolved over time, based on quarterly financial data. Check RENAU.UNSP.ARD 1/5 EO-20 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
RENAU.UNSP.ARD 1/5 EO-20 Competitors by Total Liabilities
The table below lists competitors of RENAU.UNSP.ARD 1/5 EO-20 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hyundai Rotem Co
KO:064350
|
Korea | ₩3.64 Trillion |
|
SS&C Technologies Holdings Inc
NASDAQ:SSNC
|
USA | $13.77 Billion |
|
Inspur Electronic Info Industr
SHE:000977
|
China | CN¥87.92 Billion |
|
Power Finance Corporation Limited
NSE:PFC
|
India | Rs10.56 Trillion |
|
Capgemini SE
PA:CAP
|
France | €17.39 Billion |
|
Beiersdorf Aktiengesellschaft
F:BEIA
|
Germany | €4.14 Billion |
|
Sichuan Tianqi Lithium Industries Inc
SHE:002466
|
China | CN¥22.56 Billion |
|
F5 Networks Inc
NASDAQ:FFIV
|
USA | $2.75 Billion |
Liability Composition Analysis (2022–2025)
This chart breaks down RENAU.UNSP.ARD 1/5 EO-20's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see RENAU.UNSP.ARD 1/5 EO-20 (56S0) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.94 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.48 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how RENAU.UNSP.ARD 1/5 EO-20's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for RENAU.UNSP.ARD 1/5 EO-20 (2022–2025)
The table below shows the annual total liabilities of RENAU.UNSP.ARD 1/5 EO-20 from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €3.86 Billion ≈ $4.51 Billion |
-8.85% |
| 2024-12-31 | €4.23 Billion ≈ $4.95 Billion |
-16.29% |
| 2023-12-31 | €5.06 Billion ≈ $5.91 Billion |
+98.19% |
| 2022-12-31 | €2.55 Billion ≈ $2.98 Billion |
-- |
About RENAU.UNSP.ARD 1/5 EO-20
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transp… Read more